Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics is expected to have a positive outlook due to its high potential for growth in the multi-billion-dollar market of sleep-disordered breathing. The company's Vivos System offers a non-surgical, non-invasive, and low-cost solution for patients with mild-to-moderate obstructive sleep apnea, giving it a favorable product positioning. Its recent financial results have also shown strong revenue growth and improved gross margins, indicating potential for sustainable profitability. The company's transition to a sleep-center model and its ongoing efforts to drive topline growth are also seen as positive factors. However, risks to the company's share price target include low visibility on expenses and potential dilution from financing.

Vivos Therapeutics is in a period of transition to a new distribution strategy and consolidating sleep center operations. This has resulted in a widened net loss, and while management is focused on improving the company's economics and achieving cash flow breakeven, more financing will likely be required. However, Vivos' customized oral appliance technology that has the potential to reduce or eliminate dependence on the current standard of care for sleep-disordered breathing presents a strong growth opportunity. Additionally, the integration of SCN has led to a sharp uptick in revenues, though operating expenses have also increased due to acquisition and integration costs. How efficiently Vivos is able to manage these expenses will ultimately determine the success of the acquisition.